Regenerative medicine has produced a small but growing number of genuine cures, mostly for blood cancers, rare genetic disorders, and certain inherited blood diseases. Outside those areas, the field is still largely experimental. Many conditions commonly marketed as treatable by stem cell clinics, including arthritis, back pain, Alzheimer’s, and heart disease, have no FDA-approved regenerative therapy. Understanding what’s real, what’s promising, and what’s premature can save you from costly and potentially dangerous decisions.
Conditions With Approved Regenerative Cures
The clearest successes in regenerative medicine fall into a few categories. CAR-T cell therapy, which reprograms a patient’s own immune cells to hunt cancer, is approved for several types of B-cell leukemia and lymphoma. These aren’t maintenance treatments. For some patients, a single infusion has produced lasting remissions that look functionally like cures.
Gene therapies now target rare conditions that previously had no effective treatment. A one-time gene replacement can treat spinal muscular atrophy in infants, a fatal muscle-wasting disease. Other approved gene therapies address inherited retinal dystrophy (a cause of progressive blindness), severe hemophilia B, beta-thalassemia, and cerebral adrenoleukodystrophy. The common thread: these are single-gene disorders where delivering a corrected copy of one gene can fix the underlying problem.
The only stem cell products with full FDA approval are blood-forming stem cells derived from umbilical cord blood, and these are approved exclusively for disorders affecting blood production, such as certain leukemias and immune deficiencies. They are not approved for any other use.
What Regenerative Medicine Cannot Cure Yet
This is where the gap between marketing and science is widest. The FDA has explicitly stated that no approved stem cell or exosome product exists for:
- Orthopedic conditions: osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain
- Neurological disorders: multiple sclerosis, ALS, Alzheimer’s disease, Parkinson’s disease, epilepsy, or stroke
- Cardiovascular or lung diseases: heart disease, emphysema, or COPD
- Other conditions: autism, macular degeneration, blindness, chronic pain, or fatigue
Despite this, hundreds of clinics in the U.S. advertise stem cell injections for knee arthritis, back pain, and other conditions on this list. These treatments are not FDA-approved, have not been proven safe or effective in rigorous trials, and in some cases have caused serious harm, including infections, tumors, and vision loss.
Promising Trials That Aren’t Cures Yet
Type 1 Diabetes
One of the most exciting developments involves lab-grown insulin-producing cells. In a clinical trial of a stem cell-derived islet cell therapy, 10 of 12 participants (83%) became completely independent of insulin injections. That’s a remarkable result for a disease that currently requires lifelong management. The therapy is not yet approved, but it’s further along than most people realize.
Heart Failure After Heart Attack
Stem cell treatments for heart damage have shown modest but measurable benefit. In trials where stem cells were delivered after a heart attack, patients saw their heart’s pumping efficiency improve by about 6 percentage points more than patients who didn’t receive the cells. That’s meaningful, roughly the kind of improvement that can reduce heart failure symptoms, but it’s not a cure, and these therapies remain experimental.
Spinal Cord Injury
Neural stem cell transplants have been tested in patients with chronic spinal cord injuries. In a five-year follow-up study of four patients, two showed durable neurological improvement, including gains in motor function, sensation, and muscle activity on electrical testing. Progress is slow and inconsistent, but the fact that any recovery occurred in chronic injuries, where the conventional expectation is no further improvement, is notable.
Dry Macular Degeneration
The National Eye Institute is testing stem cell-derived patches placed behind the retina to replace damaged cells in advanced dry macular degeneration. Researchers have been transparent that the patch is not expected to restore fine vision like reading ability in patients who already have severe vision loss. The goal at this stage is proving the approach is safe and can slow further degeneration.
Bioengineered Organs
3D bioprinting of human organs generates a lot of headlines but remains far from the clinic. No published clinical trials have tested a 3D bioprinted organ in a human patient. Current research is focused on using bioprinted tissue models to predict how patients will respond to chemotherapy, which is useful but very different from printing a transplantable kidney.
Why Approved Gene Therapies Cost So Much
Regenerative cures that do exist carry staggering price tags. Gene therapy prices now exceed $3 million per dose in some cases. The logic behind these prices is that a one-time treatment replaces decades of ongoing care, but the upfront cost creates real access problems. Insurance companies have started offering subscription-style coverage plans, where employers pay a small monthly fee per employee (roughly $0.85 to $1.70) to cover all approved gene therapies if anyone on the plan ever needs one. These models are still new and don’t cover experimental treatments.
For the therapies that are approved, the cost question is less about whether they work and more about who can get them. A family dealing with spinal muscular atrophy in a newborn may face an entirely different financial reality depending on their insurer.
How to Evaluate Regenerative Medicine Claims
If a clinic advertises stem cell treatment for a condition on the FDA’s “not approved” list, that’s a red flag. Legitimate clinical trials are registered on ClinicalTrials.gov, don’t charge patients for the experimental treatment itself, and are conducted through accredited research institutions. A clinic asking you to pay thousands of dollars out of pocket for an unproven injection is operating outside the framework of evidence-based medicine.
The field is genuinely advancing. The pipeline of therapies expected by 2026 includes treatments for additional blood cancers, neurological conditions, and even higher-prevalence diseases like wet macular degeneration and knee osteoarthritis. But “in the pipeline” is not the same as “available now.” The honest answer is that regenerative medicine can cure a small number of cancers and rare genetic diseases today, and may treat a much wider range of conditions in the coming decade, but most of the conditions people hope it will fix are still years away from proven therapies.